Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. …

Aim The aim of this paper is to describe the clinical features of COVID‐19‐related
encephalopathy and their metabolic correlates using brain 2‐desoxy‐2‐fluoro‐D‐glucose (FDG)‐…

Objective To compare the natural history of familial transthyretin amyloid polyneuropathies (FAP)
due to the Val30Met, Ser77Tyr, and Ile107Val mutations in France with the classical …

There is currently no cure for Parkinson’s disease. The symptomatic therapeutic strategy
essentially relies on dopamine replacement whose efficacy was demonstrated more than 50 …

Objective Survival of patients with monogenic Parkinson's disease may depend on the
causative genes associated with the disease. In this study, we compare survival of patients with …

Objective To clearly define transthyretin familial amyloid polyneuropathies (TTR-FAPs)
fulfilling definite clinical and electrophysiologic European Federation of Neurological Societies/…

Importance There is evidence of central nervous system impairments associated with coronavirus
disease 2019 (COVID-19) infection, including encephalopathy. Multimodal monitoring …

Long-term effects of continuous subcutaneous apomorphine infusion (CSAI) on health-related
quality of life (HRQoL) and predictors of CSAI discontinuation are poorly known. Data from …

… Louise-Laure Mariani reports no disclosures related to the present work. Competing financial
interests unrelated to the present work: received research support grants from INSERM, …

Importance Huntington disease (HD), a prototypic monogenic disease, is caused by an
expanded CAG repeat in theHTTgene exceeding 35 units. However, not all patients with an HD …